Daiichi Sankyo Company Limited (D4S MU) stock market data APIs
€18.4278
0(0%)
as of July 10, 2025
Try our APIs with
free plan!
Daiichi Sankyo Company Limited Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for D4S.MU.
Prev. Close
18.4278
Open
18.4278
High
18.4278
Low
18.4278
52 wk Range
18.405-37.1107
Market Cap
38 045 M
Dividends (Yield)
0.5932
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Daiichi Sankyo Company Limited data using free add-ons & libraries
Get Daiichi Sankyo Company Limited Fundamental Data
Daiichi Sankyo Company Limited Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Daiichi Sankyo Company Limited News
New
TURALIO® Final Long-Term Data Showed Sustained Clinical Benefit in Patients with Tenosynovial Giant Cell Tumor from Open-Label Extension of ENLIVEN Phase 3 Trial
BASKING RIDGE, N.J., July 09, 2025--(BUSINESS WIRE)--Final long-term efficacy and safety results from the open-label extension of the ENLIVEN phase 3 trial showed a sustained clinical benefit from lon...
AstraZeneca (AZN) Scores FDA Approval for Datroway, First TROP2 ADC for Lung Cancer
AstraZeneca PLC (NASDAQ:AZN) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company announced that the FDA had granted accelerated approval to Datroway for the treatment ...
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
Merck MRK has built a substantial portfolio of new products and pipeline candidates in areas like oncology, vaccines, neuroscience, and infectious disease. Merck’s phase III pipeline has almost tri...
FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer
AstraZeneca AZN announced that the FDA has expanded the label of its cancer drug Datroway for a second indication — non-small cell lung cancer (NSCLC). The drug has been developed in partnership wit...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
